Navigation Links
Maverix Biomics Forms Strategic Co-Marketing Alliance with QIAGEN
Date:11/13/2013

PHOENIX, Nov. 13, 2013 /PRNewswire/ -- Maverix Biomics Inc., today announced at the Association of Molecular Pathology (AMP) 2013 Annual Meeting in Phoenix, Arizona that the company has signed a non-exclusive strategic co-marketing agreement with QIAGEN to streamline the interpretation of raw next-generation sequencing (NGS) data into meaningful and actionable insights. The Maverix Analytic Platform will complement QIAGEN's sample-to-insight workflow by providing easy, three-step, push-button data analysis, which will be integrated with QIAGEN's Ingenuity® iReport™ biological data interpretation solution. Financial terms were not disclosed.

The combination of the Maverix Analytic Platform and QIAGEN's Ingenuity® iReport™ is the first integrated solution of its kind to quickly produce genome alignment, biological meaning of expression data and a better understanding of what may impact disease pathways, such as cancer.  Today at AMP, executives from QIAGEN, Maverix Biomics and Pathway Genomics are participating in a corporate workshop entitled "Simplifying RNA-based Next Generation Sequencing Workflows," which will address the adoption of NGS in fields such as clinical research and diagnostics as well as the workflow challenges in these settings.

"Ingenuity iReport provides the fastest way to understand the biological meaning of expression data while leveraging insights from the biomedical literature and other high-quality content in the QIAGEN Ingenuity Knowledge Base," said Ramon Felciano, Co-Founder and Senior Vice President at QIAGEN Redwood City.  "The combination of iReport and the Maverix Biomics platform provides our mutual customers a new and enhanced solution that enables them to quickly achieve actionable insights that will ultimately accelerate their advancement into a clinical or diagnostic environment."

"We are especially pleased at how readily the Maverix Analytic Platform integrates with the Ingenuity iReport solution to provide a more seamless instrument-to-insight experience," said Dr. Paul Pickering, Maverix Chief Operating Officer. "Our customers find QIAGEN's sample-to-result vision compelling, especially as next generation sequencing technology transitions from the research lab to the clinic."

Drs. Ervin Epstein and Grace Wang at the Children's Hospital Oakland Research Institute (CHORI) are leading a program whose goal is to understand better the molecular changes underlying the development of basal cell carcinomas, the most common of all human cancers. More than 15 years ago, Dr. Epstein was part of a worldwide effort that identified hedgehog signaling dysregulation as being the pivotal event in the conversion of normal skin keratinocytes into these cancers. Today, his team at CHORI is assessing RNA expression in different murine models to try to investigate what additional hurdles these cells must overcome on their carcinogenic journey.

"The combination of the Maverix Analytic Platform and iReport have helped us move from raw RNASeq data to testable hypotheses in a rapid and seamless manner, a process crucial for us non-cognoscenti," said Dr. Epstein. "Hopefully further study of these leads will advance our goal of developing new preventive and therapeutic measures."

About the Maverix Analytic Platform
Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven, open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analysis with reliable, scientifically recommended configurations, as cited in peer- reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including the UCSC Genome Browser, the world's most widely used genome browser.

About Maverix Biomics
Based in San Mateo CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com.


'/>"/>
SOURCE Maverix Biomics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cast Covers Transforms Broken Limbs into 3-D Animals with new CastCritterz! for Children
2. Conroe Physician Performs Laser Tattoo Removal with Astanza Duality Technology at Vanishing Ink MD
3. Increasing Affluence and Legislative Reforms are Transforming Polands Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies
4. KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
5. Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013
6. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
7. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
8. Safety Net Clinic and Hospital User Group Forms to Collaborate on 340B Drug Program Best Practices and Transparency Initiatives
9. Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today
10. TeamHealth Medical Call Center Forms Clinical Advisory Committee
11. Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... England , May 24, 2016 ... and Education in Clinical Neurophysiology  Elsevier ... information products and services, today announced the launch of ... an open access journal that focuses on clinical practice ... research, case reports, clinical series, normal values and didactic ...
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... LONDON , May 23, 2016 ... Surgical Devices, Diagnostics and Monitoring, and Vision Care ... Market? Which areas are going to grow at the ... potential revenues to 2026, assessing data, trends, opportunities and ... tables, charts, and graphs. Discover the most lucrative areas ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... , ... Boyd Industries, a leading supplier of dental chairs and cabinetry ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of ... Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
(Date:5/24/2016)... Bethpage, NY (PRWEB) , ... May 24, 2016 , ... ... of this growing trend, more gluten-free products are available and easily accessible. Whether someone ... they want to cater to a certain diet, King Kullen Grocery stocks their shelves ...
(Date:5/24/2016)... ROCKVILLE, Maryland (PRWEB) , ... May 24, 2016 ... ... today announced the appointment of Jonathan (Jon) Otterstatter to its board ... and is a proven leader in the development of technological innovations that lead ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in ... enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a Young ... location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to the ...
Breaking Medicine News(10 mins):